September 2020 – Page 7

Sep 19 2020

NIH to promote early intervention for schizophrenia via public-private partnership

by Clinical Editor

No Comments

The National Institutes of Health announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing...

Sep 19 2020

Uncategorized

Schizophrenia Tx Eases Depression in Bipolar Disorder

by Clinical Editor

No Comments

An atypical antipsychotic approved to treat schizophrenia improved depressive episodes for patients with bipolar disorder, according to an industry-supported trial. In a group of 333 patients with …

Sep 19 2020

Uncategorized

Boehringer’s schizophrenia med boosts cognition in phase 2

by Clinical Editor

No Comments

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or …

Sep 18 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 18 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Sep 18 2020

Uncategorized

Schizophrenia: Nurture cannot overcome nature

by Clinical Editor

No Comments

In the great nature vs. nurture debate, nature just got a win. UCI research led by Amal Alachkar found that too much of a certain amino acid in utero caused...

Sep 18 2020

Uncategorized

Scientists awarded $52 million NIH grant to study schizophrenia cause and effect

by Clinical Editor

No Comments

UCLA researchers and their colleagues from two other institutions have been awarded a $52 million grant from the National Institutes of Health to lead an international study to better understand...

Sep 18 2020

Uncategorized

NIH to promote early intervention for schizophrenia via public-private partnership

by Clinical Editor

No Comments

The National Institutes of Health announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing...

Sep 17 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 17 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Month: September 2020